These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 33555272)

  • 1. RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.
    Matthijssens F; Sharma ND; Nysus M; Nickl CK; Kang H; Perez DR; Lintermans B; Van Loocke W; Roels J; Peirs S; Demoen L; Pieters T; Reunes L; Lammens T; De Moerloose B; Van Nieuwerburgh F; Deforce DL; Cheung LC; Kotecha RS; Risseeuw MD; Van Calenbergh S; Takarada T; Yoneda Y; van Delft FW; Lock RB; Merkley SD; Chigaev A; Sklar LA; Mullighan CG; Loh ML; Winter SS; Hunger SP; Goossens S; Castillo EF; Ornatowski W; Van Vlierberghe P; Matlawska-Wasowska K
    J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33555272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
    Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
    Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia.
    Blackburn PR; Smadbeck JB; Znoyko I; Webley MR; Pitel BA; Vasmatzis G; Xu X; Greipp PT; Hoppman NL; Ketterling RP; Baughn LB; Lindsey KG; Schandl CA; Wolff DJ; Peterson JF
    Genes Chromosomes Cancer; 2020 Jul; 59(7):422-427. PubMed ID: 32196814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rare
    Panagopoulos I; Andersen K; Eilert-Olsen M; Rognlien AG; Munthe-Kaas MC; Micci F; Heim S
    Cancer Genomics Proteomics; 2021; 18(2):121-131. PubMed ID: 33608309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Ferrari A; Ghelli Luserna Di Rora A; Domizio C; Papayannidis C; Simonetti G; Maria Hernández-Rivas J; Rondoni M; Giglio F; Abruzzese E; Imovilli A; Iacobucci I; Calistri D; Martinelli G
    Br J Haematol; 2021 Mar; 192(6):e139-e144. PubMed ID: 33314053
    [No Abstract]   [Full Text] [Related]  

  • 6. The stem cell-specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia.
    Al-Kershi S; Bhayadia R; Ng M; Verboon L; Emmrich S; Gack L; Schwarzer A; Strowig T; Heckl D; Klusmann JH
    Blood Adv; 2019 Dec; 3(24):4252-4263. PubMed ID: 31867596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
    Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
    Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
    Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
    Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia.
    Sharma R; Incoronato A; Zhang C; Jayanthan A; Shah R; Narendran A
    J Pediatr Hematol Oncol; 2023 Aug; 45(6):e750-e756. PubMed ID: 37494611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia.
    Hyrenius-Wittsten A; Pilheden M; Sturesson H; Hansson J; Walsh MP; Song G; Kazi JU; Liu J; Ramakrishan R; Garcia-Ruiz C; Nance S; Gupta P; Zhang J; Rönnstrand L; Hultquist A; Downing JR; Lindkvist-Petersson K; Paulsson K; Järås M; Gruber TA; Ma J; Hagström-Andersson AK
    Nat Commun; 2018 May; 9(1):1770. PubMed ID: 29720585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells.
    Oo ZM; Illendula A; Grembecka J; Schmidt C; Zhou Y; Esain V; Kwan W; Frost I; North TE; Rajewski RA; Speck NA; Bushweller JH
    Leuk Lymphoma; 2018 Sep; 59(9):2188-2200. PubMed ID: 29249175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/
    Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD
    Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Methylation of CpG island in promoter region of RUNX2 gene and its expression in HOX11(+) acute T lymphoblastic leukemia].
    Jia JS; Salvatore S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):273-8. PubMed ID: 23628015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric predictive scoring systems for common fusions ETV6/RUNX1, BCR/ABL1, TCF3/PBX1 and rearrangements of the KMT2A gene, proposed for the initial cytogenetic approach in cases of B-acute lymphoblastic leukemia.
    Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Marinakis T; Kostopoulos IV; Stiakaki E; Polychronopoulou S; Paterakis G
    Int J Lab Hematol; 2019 Jun; 41(3):364-372. PubMed ID: 30730614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy-induced Deletion in 11q23 Leading to Fusion of
    Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
    Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLL/KMT2A translocations in diffuse large B-cell lymphomas.
    Gindin T; Murty V; Alobeid B; Bhagat G
    Hematol Oncol; 2015 Dec; 33(4):239-46. PubMed ID: 25131304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
    Sharma ND; Nickl CK; Kang H; Ornatowski W; Brown R; Ness SA; Loh ML; Mullighan CG; Winter SS; Hunger SP; Cannon JL; Matlawska-Wasowska K
    Cancer Sci; 2019 Jun; 110(6):1931-1946. PubMed ID: 30974024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
    Menu E; Beaufils N; Usseglio F; Balducci E; Lafage Pochitaloff M; Costello R; Gabert J
    BMC Cancer; 2017 May; 17(1):363. PubMed ID: 28535805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute leukemias harboring KMT2A/MLLT10 fusion: a 10-year experience from a single genomics laboratory.
    Peterson JF; Sukov WR; Pitel BA; Smoley SA; Pearce KE; Meyer RG; Williamson CM; Smadbeck JB; Vasmatzis G; Hoppman NL; Greipp PT; Baughn LB; Ketterling RP
    Genes Chromosomes Cancer; 2019 Aug; 58(8):567-577. PubMed ID: 30707474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid Sarcoma of the Testis in Children: Clinicopathologic and Immunohistochemical Characteristics With KMT2A (MLL) Gene Rearrangement Correlation.
    El Jamal SM; Salama A; Marcellino BK; Abulsayen HA; Zhou X; Hassan M; Firpo-Betancourt A; Saad AG
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):501-507. PubMed ID: 31241561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.